Company profile

Christopher Peetz
Incorporated in
Fiscal year end
IRS number

MIRM stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


7 May 20
9 Jul 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Net income -21.31M -17.95M -15.09M -13.56M
Diluted EPS -0.86 -0.11 -0.84 -5.31
Operating income -22.03M -18.66M -15.87M -14.03M
Net change in cash 60.07M -18.84M -11M
Cash on hand 72.04M 11.97M 30.81M 41.82M

Financial data from company earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
11 Jun 20 Grey Michael G Stock Option Common Stock Grant Aquire A No 16.71 17,000 284.07K 17,000
11 Jun 20 Brege Laura Stock Option Common Stock Grant Aquire A No 16.71 14,167 236.73K 14,167
11 Jun 20 O'Donnell Niall Stock Option Common Stock Grant Aquire A No 16.71 17,000 284.07K 17,000
11 Jun 20 Patrick J Heron Stock Option Common Stock Grant Aquire A No 16.71 17,000 284.07K 17,000
11 Jun 20 Fischer Laurent Stock Option Common Stock Grant Aquire A No 16.71 17,000 284.07K 17,000
73.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 44 41 +7.3%
Opened positions 8 15 -46.7%
Closed positions 5 14 -64.3%
Increased positions 21 12 +75.0%
Reduced positions 5 7 -28.6%
13F shares
Current Prev Q Change
Total value 260.45M 398.45M -34.6%
Total shares 18.6M 16.25M +14.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
NEA Management 4.19M $58.63M 0.0%
Frazier Management 3.57M $49.94M 0.0%
Deerfield Management 3.45M $48.29M 0.0%
Novo Holdings A/S 2.45M $34.23M 0.0%
Rock Springs Capital Management 1.24M $17.4M -0.2%
POLR Polar Capital 769.43K $10.77M NEW
Baker Bros. Advisors 583.33K $8.17M +75.0%
Sofinnova Investments 418.59K $5.86M NEW
Boxer Capital 317K $4.44M 0.0%
BLK BlackRock 256.74K $3.59M +41.7%
Largest transactions
Shares Bought/sold Change
POLR Polar Capital 769.43K +769.43K NEW
Sofinnova Investments 418.59K +418.59K NEW
Baker Bros. Advisors 583.33K +250K +75.0%
FMR 235K +235K NEW
AXAHF Axa 156.75K +156.75K NEW
Alyeska Investment 145.71K +118.63K +438.1%
Vanguard 173.78K +93.34K +116.1%
BLK BlackRock 256.74K +75.57K +41.7%
Millennium Management 95.3K +73.03K +327.9%
Orbimed Advisors 0 -71.3K EXIT

Financial report summary

  • We have a very limited operating history, and we have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.
  • Our business is dependent on the success of our product candidates, each of which require significant clinical testing before we can seek regulatory approval and potentially launch commercial sales.
  • We have encountered and may continue to encounter delays and difficulties enrolling patients in our clinical trials, and as a result, our clinical development activities could be delayed or otherwise adversely affected.
  • Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which could prevent or delay regulatory approval and commercialization.
  • Clinical drug development involves a lengthy and expensive process with uncertain outcomes, and results of earlier studies and trials may not be predictive of future trial results.
  • Any delays in the commencement or completion, or termination or suspension, of our clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
  • If the market opportunities for our product candidates are smaller than we believe they are, our future revenue may be adversely affected, and our business may suffer.
  • Obtaining and maintaining regulatory approval for a product candidate in one jurisdiction does not mean that we will be successful in obtaining regulatory approval for that product candidate in other jurisdictions.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or result in significant negative consequences following marketing approval, if any.
  • Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could negatively impact our business.
  • Even if we obtain regulatory approval for our product candidates, our product candidates may not gain market acceptance among physicians, patients, tertiary care centers, transplant centers and others in the medical community.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates which could make it difficult for us to sell our product candidates profitably.
  • Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set.
  • A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.
  • If we fail to develop our current and any future product candidates for additional indications, our commercial opportunity will be limited.
  • We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
  • Even though we have obtained orphan drug designation for maralixibat in PFIC and ALGS, we may not be able to obtain or maintain the benefits associated with orphan drug status, including market exclusivity.
  • Although the FDA has granted Rare Pediatric Disease Designation for maralixibat for ALGS, an NDA for maralixibat, if approved, may not meet the eligibility criteria for a priority review voucher.
  • Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.
  • We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.
  • We will need to grow the size of our organization, and we may experience difficulties in managing this growth.
  • Business disruptions could seriously harm our future revenues and financial condition and increase our costs and expenses.
  • Our employees, independent contractors, principal investigators, CROs, consultants, strategic partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • We are subject to restrictive regulations governing the use, processing and cross-border transfer of personal information.
  • We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.
  • We rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.
  • We rely completely on third parties to manufacture our preclinical and clinical drug supplies and we intend to rely on third parties to produce commercial supplies of each of our product candidates, if approved, and these third parties may fail to obtain and maintain regulatory approval for their facilities, fail to provide us with sufficient quantities of drug product or fail to do so at acceptable quality levels or prices.
  • If we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages.
  • We will need substantial additional financing to develop our product candidates and implement our operating plans. If we fail to obtain additional financing, we may be forced to delay, reduce or eliminate our product development programs or commercialization efforts.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
  • Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • If we are unable to obtain and maintain sufficient intellectual property protection for our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates, if approved, may be adversely affected.
  • We currently rely on method-of-use and formulation patents to protect maralixibat and composition-of-matter and method-of-use patents to protect volixibat.
  • Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
  • We may not be able to protect our intellectual property rights throughout the world.
  • We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
  • We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
  • Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
  • The trading price of our common stock may be volatile, and you could lose all or part of your investment.
  • Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.
  • We are an emerging growth company and a smaller reporting company, and the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.
  • We have incurred and will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.
  • Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • Our failure to meet Nasdaq’s continued listing requirements could result in a delisting of our common stock.
  • Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
  • Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
  • If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
Content analysis ?
H.S. junior Avg